VIA Pharmaceuticals Completes Enrollment In Phase 2 Acute Coronary Syndrome (ACS) Trial

VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced that it has completed patient enrollment in its acute coronary syndrome (ACS) study. The ACS study is one of three Phase 2 trials investigating VIA-2291, the company’s lead product candidate in cardiovascular disease.

More: continued here

Filed under: Cardiovascular on May 17th, 2008